| Engineering AvidCARs for combinatorial antigen recognition and reversible control of CAR function B Salzer, CM Schueller, CU Zajc, T Peters, MA Schoeber, B Kovacic, ... Nature Communications 11 (1), 4166, 2020 | 68 | 2020 |
| A conformation-specific ON-switch for controlling CAR T cells with an orally available drug CU Zajc, M Dobersberger, I Schaffner, G Mlynek, D Pühringer, B Salzer, ... Proceedings of the National Academy of Sciences 117 (26), 14926-14935, 2020 | 63 | 2020 |
| Turning the tables on cytomegalovirus: targeting viral Fc receptors by CARs containing mutated CH2–CH3 IgG spacer domains J Proff, CU Brey, A Ensser, W Holter, M Lehner Journal of translational medicine 16, 1-12, 2018 | 40 | 2018 |
| Cytomegalovirus-infected cells resist T cell mediated killing in an HLA-recognition independent manner J Proff, C Walterskirchen, C Brey, R Geyeregger, F Full, A Ensser, ... Frontiers in microbiology 7, 844, 2016 | 29 | 2016 |
| Driving CARs with alternative navigation tools–the potential of engineered binding scaffolds CU Zajc, B Salzer, JM Taft, ST Reddy, M Lehner, MW Traxlmayr The FEBS journal 288 (7), 2103-2118, 2021 | 27 | 2021 |
| Engineering strategies to overcome the stability–function trade-off in proteins M Teufl, CU Zajc, MW Traxlmayr ACS Synthetic Biology 11 (3), 1030-1039, 2022 | 16 | 2022 |
| A gB/CD3 bispecific BiTE antibody construct for targeting Human Cytomegalovirus-infected cells CU Brey, J Proff, N Teufert, B Salzer, J Brozy, M Münz, J Pendzialek, ... Scientific Reports 8 (1), 17453, 2018 | 11 | 2018 |
| Affinity and StabilityStabilities Analysis of Yeast Displayed Proteins CU Zajc, M Teufl, MW Traxlmayr Yeast Surface Display, 155-173, 2022 | 6 | 2022 |
| An engineering strategy to target activated EGFR with CAR T cells M Dobersberger, D Sumesgutner, CU Zajc, B Salzer, E Laurent, ... Cell Reports Methods 4 (4), 2024 | 1 | 2024 |
| Solving the mystery of the FMC63-CD19 affinity J Seigner, CU Zajc, S Dötsch, C Eigner, E Laurent, DH Busch, M Lehner, ... Scientific Reports 13 (1), 23024, 2023 | | 2023 |
| ENGINEERING AVIDCARS FOR COMBINATORIAL ANTIGEN RECOGNITION S Balaji, B Salzer, C Schueller, C Zajc, M Traxlmayr, M Lehner HUMAN GENE THERAPY 34 (21-22), A13-A13, 2023 | | 2023 |
| ENGINEERING AVIDCARS FOR COMBINATORIAL ANTIGEN RECOGNITION M Lehner, B Salzer, C Schueller, C Zajc, M Traxlmayr HUMAN GENE THERAPY 33 (7-8), A18-A19, 2022 | | 2022 |
| ENGINEERING AVIDCARS FOR SMALL MOLECULE-DEPENDENT CAR T CELL REGULATION B Salzer, C Schueller, C Zajc, M Lehner, M Traxlmayr HUMAN GENE THERAPY 33 (7-8), A11-A11, 2022 | | 2022 |
| A CONFORMATION-SPECIFIC ON-SWITCH FOR CONTROLLING CAR T CELLS WITH AN ORALLY AVAILABLE DRUG E Sylvander, C Zajc, M Dobersberger, I Schaffner, B Salzer, M Traxlmayr, ... HUMAN GENE THERAPY 33 (7-8), A16-A17, 2022 | | 2022 |
| STRATEGY TO INCREASE TUMOR SPECIFICITY OF EGFR-TARGETING THERAPIES M Dobersberger, E Laurent, E Sylvander, J Seigner, M Teufl, B Salzer, ... HUMAN GENE THERAPY 33 (7-8), A17-A18, 2022 | | 2022 |
| POTENTIAL CORRELATION BETWEEN THERMOSTABILITIES OF ANTIGEN BINDING DOMAINS AND CAR EXPRESSION LEVELS M Teufl, F Schubert, C Zajc, B Salzer, M Lehner, M Traxlmayr HUMAN GENE THERAPY 33 (7-8), A42-A42, 2022 | | 2022 |
| INFLUENCE OF CD19 DENSITY AND AFFINITY ON CAR T CELL ACTIVATION: A COMBINATORIAL ANALYSIS OF DIFFERENT PARAMETERS AND THEIR IMPACT ON CAR ACTIVITY J Seigner, E Laurent, C Zajc, B Salzer, C Obinger, M Lehner, M Traxlmayr HUMAN GENE THERAPY 33 (7-8), A40-A41, 2022 | | 2022 |
